Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANLNASDAQ:MENASDAQ:NATRNASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$2.00+6.1%$1.95$1.10▼$10.70$73.62M-0.9913,273 shs23,577 shsME23andMe$0.50-35.3%$0.51$0.53▼$12.32$13.36M1.191.33 million shs29.28 million shsNATRNature's Sunshine Products$15.17+3.3%$12.81$10.81▼$18.06$277.28M1.146,485 shs50,101 shsTERNTerns Pharmaceuticals$3.14+2.5%$2.80$1.87▼$11.40$272.93M-0.161.53 million shs345,060 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-1.94%-2.42%-9.25%-19.69%-82.02%ME23andMe0.00%0.00%0.00%-77.26%-95.42%NATRNature's Sunshine Products-1.01%+1.45%+24.20%+3.38%-3.67%TERNTerns Pharmaceuticals+1.66%+2.34%+4.08%-17.07%-51.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye1.5784 of 5 stars3.53.00.00.01.80.00.0ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ANATRNature's Sunshine Products2.1371 of 5 stars2.53.00.00.02.71.71.3TERNTerns Pharmaceuticals4.101 of 5 stars3.31.00.04.14.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 3.00Buy$9.00351.13% UpsideME23andMe 1.00SellN/AN/ANATRNature's Sunshine Products 3.00Buy$18.3320.85% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63398.41% UpsideCurrent Analyst Ratings BreakdownLatest ME, ANL, TERN, and NATR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.005/7/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.004/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.004/14/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/7/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M14.72N/AN/AN/A∞ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21NATRNature's Sunshine Products$456.62M0.61$1.74 per share8.73$8.36 per share1.81TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$104.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ANATRNature's Sunshine Products$15.08M$0.5317.17∞N/A3.81%11.08%7.23%8/6/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)Latest ME, ANL, TERN, and NATR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A5/6/2025Q1 2025NATRNature's Sunshine Products$0.16$0.25+$0.09$0.25$109.39 million$113.25 million3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ANATRNature's Sunshine Products$0.402.64%N/A75.47%N/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A1.85N/AME23andMeN/A1.050.91NATRNature's Sunshine ProductsN/A2.441.51TERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%ME23andMe36.10%NATRNature's Sunshine Products79.40%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AME23andMe26.32%NATRNature's Sunshine Products5.60%TERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableME23andMe77026.83 million19.77 millionNot OptionableNATRNature's Sunshine Products85018.35 million17.61 millionOptionableTERNTerns Pharmaceuticals4087.34 million72.11 millionNot OptionableME, ANL, TERN, and NATR HeadlinesRecent News About These CompaniesInfinitum Asset Management LLC Takes $1.11 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 28 at 6:10 AM | marketbeat.comTerns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potentialMay 27 at 9:15 PM | investing.comNuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 27 at 3:53 AM | marketbeat.comNorthern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 26 at 3:02 AM | marketbeat.comDeutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 25, 2025 | marketbeat.comVR Adviser LLC Sells 2,332,968 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Position Cut by Point72 Asset Management L.P.May 22, 2025 | marketbeat.comCubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 22, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) is Soleus Capital Management L.P.'s 10th Largest PositionMay 21, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Graham Capital Management L.P.May 17, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 16, 2025 | marketbeat.comTerns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701May 14, 2025 | globenewswire.comTerns Pharmaceuticals (NASDAQ:TERN) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPSMay 14, 2025 | marketbeat.comIntegral Health Asset Management LLC Increases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 14, 2025 | marketbeat.comDimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 13, 2025 | marketbeat.comDriehaus Capital Management LLC Decreases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 12, 2025 | marketbeat.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%May 10, 2025 | aaii.comIs Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | insidermonkey.comTerns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersWhy Wells Fargo Is Buying $40 Billion of Its Own StockBy Gabriel Osorio-Mazilli | May 6, 2025View Why Wells Fargo Is Buying $40 Billion of Its Own StockAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueME, ANL, TERN, and NATR Company DescriptionsAdlai Nortye NASDAQ:ANL$2.00 +0.12 (+6.12%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Nature's Sunshine Products NASDAQ:NATR$15.17 +0.49 (+3.34%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Terns Pharmaceuticals NASDAQ:TERN$3.14 +0.08 (+2.45%) As of 03:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
